# US 8,278,436 B2 · Glycosylated warfarin analogs and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,436 B2
- Document ID: US8278436B2
- Status: Granted
- Kind: B2
- Application number: 12/512,696
- Filed: 2009-07-30
- Published: 2010-10-21
- Granted: 2012-10-02
- Earliest claimed: 2008-07-30
- Assignees: Wisconsin Alumni Research Foundation
- Inventors: Jon S. Thorson; Shannon C. Timmons
- Web page: https://patentgrep.com/patent/US8278436B2

## CPC

- C07H 15/26: Acyclic or carbocyclic radicals, substituted by hetero rings
- A61P 35/00: Antineoplastic agents
- Y10T 436/143333: Saccharide [e.g., DNA, etc.]
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

The present invention discloses a set of glycosylated warfarin analogs which are useful as anti-tumor or anti-metastatic agents and as reagents for studying sugar uptake in cells.

## Claims

### Claim 1

A composition comprising a warfarin neoglycoside having the general formula:
wherein
is a reducing sugar selected from the group consisting of L-xylose; D-lyxose; D-xylose; 2-deoxy-L-ribose; 2-deoxy-D-ribose; L-fucose; L-arabinose; D-ribose; L-lyxose; L-ribose; 2,3,4,6-tetra-O-acetyl-D-glucose; L-mycarose; 2,3,4,6-tetra-O-benzyl-D-glucose; 2,3,5-tri-O-benzyl-D-arabinofuranose; 2,3,4,6-tetra-O-benzyl-D-mannose; 2,3,5-tri-O-benzyl-D-ribofuranose; and 6-deoxy-D-glucose.

### Claim 2 (depends on 1)

A composition comprising the warfarin neoglycoside of claim 1 or a pharmaceutically acceptable salt thereof, combined with a pharmaceutically acceptable carrier.

### Claim 3

A composition comprising a warfarin neoglycoside produced when an aglycon warfarin analog containing a secondary alkoxylamine moiety having the structure:
is contacted with a reducing sugar selected from the group consisting of L-xylose; D-lyxose; D-xylose; 2-deoxy-L-ribose; 2-deoxy-D-ribose; L-fucose; L-arabinose; D-ribose; L-lyxose; L-ribose; 2,3,4,6-tetra-O-acetyl-D-glucose; L-mycarose; 2,3,4,6-tetra-O-benzyl-D-glucose; 2,3,5-tri-O-benzyl-D-arabinofuranose; 2,3,4,6-tetra-O-benzyl-D-mannose; 2,3,5-tri-O-benzyl-D-ribofuranose; 6-deoxy-D-glucose; and mixtures thereof.

### Claim 4 (depends on 3)

A composition comprising the warfarin neoglycoside of claim 3 or a pharmaceutically acceptable salt thereof, combined with a pharmaceutically acceptable carrier.

### Claim 5

A method of treating cancer in a subject in need thereof comprising the step of contacting the cancer cells with an effective amount of one or more of a warfarin neoglyoside having the general formula
wherein
is a reducing sugar selected from the group consisting of L-xylose; D-lyxose; D-xylose; 2-deoxy-L-ribose; 2-deoxy-D-ribose; L-fucose; L-arabinose; D-ribose; L-lyxose; galactosamine; L-ribose; 2,3,4,6-tetra-O-acetyl-D-glucose; L-mycarose; 2,3,4,6-tetra-O-benzyl-D-glucose; 2,3,5-tri-O-benzyl-D-arabinofuranose; 2,3,4,6-tetra-O-benzyl-D-mannose; 2,3,5-tri-O-benzyl-D-ribofuranose; and 6-deoxy-D-glucose; or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 5)

The method of claim 5, wherein the cancer cells being contacted with an effective amount of the warfarin neoglycoside or pharmaceutically acceptable salt thereof are selected from human lung adenocarcinoma cells, human colorectal adenocarcinoma cells, human ovarian adenocarcinoma cells, human central nervous system adenocarcinoma cells, and human breast adenocarcinoma cells.

### Claim 7 (depends on 6)

The method of claim 6, wherein the cancer cells being contacted are human colorectal adenocarcinoma cells.

### Claim 8 (depends on 5)

The method of claim 5, wherein the reducing sugar is selected from the group consisting of L-xylose; D-lyxose; D-xylose; 2-deoxy-L-ribose; 2-deoxy-D-ribose; L-fucose; L-lyxose; 2,3,4,6-tetra-O-acetyl-D-glucose; L-mycarose; 2,3,5-tri-O-benzyl-D-arabinofuranose; 2,3,4,6-tetra-O-benzyl-D-mannose; 2,3,5-tri-O-benzyl-D-ribofuranose; and 6-deoxy-D-glucose.

### Claim 9

A method of studying sugar uptake in cells comprising the steps of:
(a) contacting cells with a warfarin neoglyoside having the general formula
wherein
is a reducing sugar selected from the group consisting of L-xylose; D-lyxose; D-xylose; 2-deoxy-L-ribose; 2-deoxy-D-ribose; L-fucose; L-arabinose; D-ribose; L-lyxose; 2,3,4,6-tetra-O-acetyl-D-glucose; L-mycarose; 2,3,4,6-tetra-O-benzyl-D-glucose; 2,3,5-tri-O-benzyl-D-arabinofuranose; 2,3,4,6-tetra-O-benzyl-D-mannose; 2,3,5-tri-O-benzyl-D-ribofuranose; and 6-deoxy-D-glucose, and
(b) measuring the amount of the warfarin neoglycoside taken up by the cells.

### Claim 10 (depends on 9)

The method of claim 9, wherein the step of measuring the amount of the warfarin neoglycoside taken up by the cells is performed by a fluorescence-based assay.
